Basal 18F-FDG PET/CT as a predictive biomarker of tumor response for neoadjuvant therapy in breast cancer
- 1 March 2016
- journal article
- Published by Elsevier in Revista Española de Medicina Nuclear e Imagen Molecular
- Vol. 35 (2) , 81-87
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Glycolytic activity with 18F-FDG PET/CT predicts final neoadjuvant chemotherapy response in breast cancerTumor Biology, 2014
- Breast Cancer: A World of Differences2014
- Breast cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG–PET after the first courseBreast Cancer Research and Treatment, 2011
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Annals of Oncology, 2011
- Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristicsBreast Cancer Research and Treatment, 2011
- Dual time point FDG-PET/CT imaging… Potential tool for diagnosis of breast cancerClinical Radiology, 2008
- Clinicopathological and Prognostic Relevance of Uptake Level using 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging (18F-FDG PET/CT) in Primary Breast CancerJapanese Journal of Clinical Oncology, 2008
- Comparison of triple‐negative and estrogen receptor‐positive/progesterone receptor‐positive/HER2‐negative breast carcinoma using quantitative fluorine‐18 fluorodeoxyglucose/positron emission tomography imaging parametersCancer, 2007
- Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27Journal of Clinical Oncology, 2006